Regulation of chondrocyte matrix metalloproteinase gene expression

Proteases in Health and Disease

Volumn , Issue , 2013, Pages 63-77

  Malemud, Charles J ^a,b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arthritis; Chondrocyte; Gene transcription; Matrix metalloproteinase; Signal transduction; Transcription factor

Indexed keywords

EID: 84926388836     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-9233-7_5     Document Type: Chapter

References (94)

1. Malemud CJ (2006) Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 11:1696-1701.
2. Mancini A, Di Battista JA (2006) Transcriptional regulation of matrix metalloproteinase gene expression in health and disease. Front Biosci 11:423-446.
3. Nagase H, Woessner JF Jr (1999) Matrix metalloproteinases. J Biol Chem 274:322-329.
4. Reuben PM, Cheung HS (2006) Regulation of matrix metalloproteinase (MMP) gene expression by protein kinases. Front Biosci 11:1199-1215.
5. Flannery CR (2006) MMPs and ADAMTS: functional studies. Front Biosci 11:544-569.
6. Troeberg L, Nagase H (2012) Proteases involved in cartilage matrix degradation in osteoarthritis. Biochim Biophys Acta 1824:133-145.
7. Sylvester J, Ahmad R, Zafarullah M (2013) Role of Sp1 transcription factor in interleukin-1- induced ADAMTS-4 (aggrecanase-1) gene expression in human articular chondrocytes. Rheumatol Int 33:517-522.
8. Dechow TN, Pedranzini L, Leitch A et al (2004) Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci U S A 101:10602-10607.
9. Burrage PS, Mix KS, Brinckerhoff CE (2006) Matrix metalloproteinases: role in arthritis. Front Biosci 11:529-543.
10. Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92:827-839.
11. Malemud CJ (2006) Matrix metalloproteinases: role in skeletal development and growth plate disorders. Front Biosci 11:1702-1715.
12. Brauer PR (2006) MMPs-role in cardiovascular development and disease. Front Biosci 11:447-478.
13. Fingleton B (2006) Matrix metalloproteinases: role in cancer and metastasis. Front Biosci 11:479-491.
14. Gasche I, Soccal PM, Kanemitsu M et al (2006) Matrix metalloproteinases and diseases of the central nervous system with special emphasis on ischemic brain. Front Biosci 11:1289-1301.
15. Malemud CJ, Pearlman E (2009) Targeting JAK/STAT signaling pathway in infl ammatory diseases. Curr Signal Transduct Ther 4:201-221.
16. Tong KM, Chen CP, Huang KC et al (2011) Adiponectin increases MMP-3 expression in human chondrocytes through AdipoR1 signaling pathway. J Cell Biochem 112:1431-1440.
17. Haeusgen W, Herdegen T, Waetzig V (2011) The bottleneck of JNK signaling: molecular and functional characteristics of MKK4 and MKK7. Eur J Cell Biol 90:536-544.
18. Guma M, Firestein GS (2012) c-Jun-N-terminal kinase in infl ammation and rheumatic diseases. Open Rheumatol J 6:220-231.
19. Davies C, Tournier C (2012) Exploring the function of the JNK (c-Jun N-terminal kinase) signalling pathway in physiological and pathological processes to design novel therapeutic strategies. Biochem Soc Trans 40:85-89.
20. Martel-Pelletier J, Welsch DJ, Pelletier J-P (2001) Metalloproteases and inhibitors in arthritic diseases. Best Pract Res Clin Rheumatol 15:805-829.
21. Pozgan U, Caglic D, Rozman B et al (2010) Expression and activity profi ling of selected cysteine cathepsins and matrix metalloproteinases in synovial fl uids from patients with rheumatoid arthritis and osteoarthritis. Biol Chem 391:571-579.
22. Kokkonen H, Soderstrom I, Rocklov J et al (2010) Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum 62:383-391.
23. Berenbaum F (2011) Osteoarthritis year 2010 in review: pharmacological therapies. Osteoarthritis Cartilage 19:361-365.
24. Westermarck J, Kähäri VM (1999) Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13:781-792.
25. Overall CM, Wrana JL, Sodek J (1991) Transcriptional and post-translational regulation of 72 kDa gelatinase/Type IV collagenase by transforming growth factor-ß1 in human fi broblasts. Comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression. J Biol Chem 266:14064-14071.
26. Delaney AM, Brinckerhoff CE (1992) Post-transcriptional regulation of collagenase and stromelysin gene expression by epidermal growth factor and dexamethasone in cultured human fi broblasts. J Cell Biochem 50:400-410.
27. Bui C, Barter MJ, Scott JL et al (2012) cAMP response element-binding (CREB) recruitment following a specifi c CpG demethylation leads to the elevated expression of the matrix metalloproteinase 13 in human articular chondrocytes and osteoarthritis. FASEB J 26:3000-3011.
28. Karin M, Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 18:621-663.
29. Malemud CJ, Schulte ME (2008) Is there a fi nal common pathway for arthritis? Future Rheumatol 3:253-268.
30. Chakraborti S, Mandal M, Das S et al (2003) Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253:269-285.
31. Vincenti MP, Brinckerhoff CE (2002) Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specifi c transcription factors. Arthritis Res 4:157-164.
32. Goldring MB, Otero M (2011) Infl ammation in osteoarthritis. Curr Opin Rheumatol 23:471-478.
33. Harris SJ, Foster JG, Ward SG (2009) PI3K isoforms as drug targets in infl ammatory diseases: lessons from pharmacological and genetic strategies. Curr Opin Investig Drugs 10:1151-1162.
34. Wisler BA, Dennis JE, Malemud CJ (2011) New organ-specifi c pharmacological strategies interfering with signaling pathways in infl ammatory disorders/autoimmune disorders. Curr Signal Transduct Ther 6:279-291.
35. Malemud CJ (2012) Apoptosis resistance in rheumatoid arthritis synovial tissue. J Clin Cell Immunol S3:006.
36. Kim KS, Oh DH, Choi HM et al (2009) Pyrrolidine dithiocarbamate, a NF-κB inhibitor, upregulates MMP-1 and MMP-13 in IL-1ß-stimulated rheumatoid arthritis fi broblast-like synoviocytes. Eur J Pharmacol 613:167-175.
37. Ducy P (2000) Cbfa1: a molecular switch in osteoblast biology. Dev Dyn 219:461-471.
38. Jimenez MJ, Balbin M, Lopez JM et al (1999) Collagenase 3 is a target of Cbfa1, a transcription factor of the runt gene family involved in bone formation. Mol Cell Biol 19:4431-4442.
39. Jimenez MJG, Balbin M, Alvarez J et al (2001) A regulatory cascade involving retinoic acid, Cbfa1, and matrix metalloproteinases is coupled to the development of a process of perichondrial invasion and osteogenic differentiation during bone formation. J Cell Biol 155:1333-1344.
40. Selvamurugan N, Kwok S, Alliston T et al (2004) Transforming growth factor-ß1 regulation of collagenase-3 expression in osteoblastic cells by cross-talk between Smad and MAPK signaling pathways and their components, Smad2 and Runx2. J Biol Chem 279:19327-19334.
41. Selvarmurugan N, Jefcoat SC, Kwok S et al (2006) Overexpression of Runx2 directed by the matrix metalloproteinase-13 promoter containing the AP-1 and Runx/RD/Cbfa sites alters bone remodeling in vivo. J Cell Biochem 99:545-557.
42. Schmucker AC, Wright JB, Cole MD et al (2012) Distal interleukin-1ß (IL-1ß) response element of human matrix metalloproteinase-13 (MMP-13) binds activator protein 1 (AP-1) transcription factors and regulates gene expression. J Biol Chem 287:1189-1197.
43. Varghese S, Rydziel S, Canalis E (2000) Basic fi broblast growth factor stimulates collagenase- 3 promoter activity in osteoblasts through an activator protein-1 binding site. Endocrinology 141:2185-2191.
44. Manabe N, Oda H, Nakamura K et al (1999) Involvement of fi broblast growth factor-2 in joint destruction of rheumatoid arthritis patients. Rheumatology (Oxford) 38:714-720.
45. Malemud CJ (2007) Growth hormone, VEGF and FGF: involvement in rheumatoid arthritis. Clin Chim Acta 375:10-19.
46. Lim H, Kim HP (2011) Matrix metalloproteinase-13 expression in IL-1ß-treated chondrocytes by activation of the p38 MAPK/c-Fos/AP-1 and JAK/STAT pathways. Arch Pharm Res 34:109-117.
47. Porte D, Tuckermann J, Becker M et al (1999) Both AP-1 and Cbfa1-like factors are required for the induction of interstitial collagenase by parathyroid hormone. Oncogene 18:667-678.
48. Shah R, Alvarez M, Jones DR et al (2004) Nmp4/CIZ regulation of matrix metalloproteinase 13 (MMP-13) response to parathyroid hormone in osteoblasts. Am J Physiol Endocrinol Metab 287:E289-E296.
49. Alvarez M, Shah R, Rhodes SJ et al (2005) Two promoters control the Nmp4/CIZ transcription factor gene. Gene 347:43-54.
50. Charoonpatrapong-Panyayong K, Shah R, Yang J et al (2007) Nmp4/CIZ contributes to fl uid shear stress induced MMP-13 gene induction in osteoblasts. J Cell Biochem 102:1202-1213.
51. Tymms MJ, Ng AY, Thomas RS et al (1997) A novel epithelial-expressed ETS gene ELF3: human and murine cDNA sequences, murine genomic organization, human mapping to 1q32.2 and expression in tissues and cancer. Oncogene 15:2449-2462.
52. Singh S, Barrett J, Sakata K et al (2002) ETS proteins and MMPs: partners in invasion and metastasis. Curr Drug Targets 3:359-367.
53. Iwai S, Amekawa S, Yomogida K et al (2008) ESE-1 inhibits the invasion of oral squamous cell carcinoma in conjunction with MMP-9 suppression. Oral Dis 14:144-149.
54. Otero M, Plumb DA, Tsuchimochi K et al (2012) E74-like factor 3 (ELF3) impacts on matrix metalloproteinase 13 (MMP13) transcriptional control in articular chondrocytes under proinfl ammatory stress. J Biol Chem 287:3559-3572.
55. Nishizawa M, Kataoka K, Goto N et al (1989) v-Maf, a viral oncogene that encodes a "leucine zipper" motif. Proc Natl Acad Sci U S A 86:7711-7715.
56. Kurokawa H, Motohashi H, Sueno S et al (2009) Structural basis of alternative DNA recognition by Maf transcription factors. Mol Cell Biol 29:6232-6244.
57. Hedge SP, Kumar A, Kurschner C et al (1998) c-Maf interacts with c-Myb to regulate transcription of an early myeloid gene during differentiation. Mol Cell Biol 18:2729-2737.
58. Akiyama H, Lefebvre V (2011) Unraveling the transcriptional regulatory machinery in chondrogenesis. J Bone Miner Res 29:390-395.
59. Huang W, Lu N, Eberspaecher H et al (2002) A new long form of c-Maf cooperates with Sox9 to activate the type II collagen gene. J Biol Chem 277:50668-50675.
60. Kerppola TK, Curran T (1994) Maf and Nrl can bind to AP-1 sites and form heterodimers with Foc and Jun. Oncogene 9:675-684.
61. Li T, Xiao J, Wu Z et al (2010) Transcriptional activation of human MMP-13 gene expression by c-Maf in osteoarthritic chondrocytes. Connect Tissue Res 51:48-54.
62. Dong JT, Chen C (2009) Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases. Cell Mol Life Sci 66:2691-2706.
63. Shinoda Y, Ogata N, Higashikawa A et al (2008) Kruppel-like factor 5 causes cartilage degradation through transactivation of matrix metalloproteinase 9. J Biol Chem 283: 24682-24689.
64. Malemud CJ (2010) Suppression of autoimmune arthritis by small molecule inhibitors of the JAK/STAT pathway. Pharmaceuticals 3:1446-1455.
65. Curtis JR, van der Helm-van Mil AH, Knevel R et al (2012) Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res 64:1794-1803.
66. Malemud CJ, Reddy SK (2008) Targeting cytokines, chemokines and adhesion molecules in rheumatoid arthritis. Curr Rheumatol Rev 4:219-234.
67. Wullaert A, Bonnet MC, Pasparakis M (2011) NF-κB in the regulation of epithelial homeostasis and infl ammation. Cell Res 21:146-158.
68. Gilmore TD, Garbati MR (2011) Inhibition of NF-κB signaling as a strategy in disease therapy. Curr Top Microbiol Immunol 349:245-263.
69. Rahman A, Fazal F (2011) Blocking NF-κB: an infl ammatory issue. Proc Am Thorac Soc 8:497-503.
70. Raskatov JA, Meier JL, Puckett JW et al (2012) Modulation of NF-κB-dependent gene transcription using programmable DNA minor groove binders. Proc Natl Acad Sci U S A 109:1023-1028.
71. Lecka-Czernik B, Gubrij I, Moerman EJ et al (1999) Inhibition of Osf2/Cbfa1 expression and terminal differentiation by PPARgamma2. J Cell Biochem 74:357-371.
72. Tintut Y, Parhami F, Le V et al (1999) Inhibition of osteoblast-specifi c transcription factor Cbfa1 by the cAMP pathway in osteoblastic cells. Ubiquitin/proteasome-dependent regulation. J Biol Chem 274:28875-28879.
73. Alliston T, Choy L, Ducy P et al (2001) TGF-ß-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast formation. EMBO J 20:2254-2272.
74. Gilbert L, He X, Farmer P et al (2002) Expression of the osteoblast differentiation factor RUNX 2 (Cbfa1/AML 3 /Pebp2aA) is inhibited by tumor necrosis factor-a. J Biol Chem 277:2695-2701.
75. Varanasi SS, Datta HK (2005) Characterisation of cytosolic FK506 binding protein 12 and its role in modulating expression of Cbfa1 and osterix in ROS 17/2.8 cells. Bone 36:243-253.
76. Lin L, Chen L, Wang H et al (2006) Adenovirus-mediated transfer of siRNA against Runx2/ Cbfa1 inhibits the formation of heterotopic ossifi cation in animal model. Biochem Biophys Res Commun 349:564-572.
77. Luan Y, Yu XP, Yang N et al (2008) p204 protein overcomes the inhibition of core binding factor a1-mediated osteogenic differentiation by Id helix-loop-helix proteins. Mol Biol Cell 19:2113-2126.
78. Ahmad R, Sylvester J, Zafarullah M (2007) MyD88, IRAK1 and TRAF6 knockdown in human chondrocytes inhibits interleukin-1-induced matrix metalloproteinase-13 gene expression and promoter activity by impairing MAP kinase activation. Cell Signal 19:2549-2557.
79. Schett G, Zwerina J, Firestein GS (2008) The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis 67:909-916.
80. Thalhamer T, McGrath MA, Harnett MM (2008) MAPKs and their relevance to arthritis and infl ammation. Rheumatology (Oxford) 47:409-414.
81. Clark AR, Dean JL (2012) The p38 MAPK pathway in rheumatoid arthritis: a sideways look. Open Rheumatol J 6:209-219.
82. Liacini A, Sylvester J, Li WQ et al (2002) Inhibition of interleukin-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-κB) transcription factors downregulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol 21:251-262.
83. Palanki MS (2002) Inhibitors of AP-1 and NF-κB mediated transcriptional activation: therapeutic potential in autoimmune disease and structural diversity. Curr Med Chem 9:219-227.
84. Malemud CJ (2006) Small molecular weight inhibitors of stress-activated and mitogenactivated protein kinases. Mini Rev Med Chem 6:689-698.
85. Malemud CJ (2007) Inhibitors of stress-activated/mitogen-activated protein kinase pathways. Curr Opin Pharmacol 7:339-343.
86. Hui A, Min WX, Tang J et al (1998) Inhibition of activator protein 1 activity by paclitaxel suppresses interleukin-1-induced collagenase and stromelysin activity by bovine chondrocytes. Arthritis Rheum 41:869-876.
87. Ahmed S, Anuntiyo J, Malemud CJ et al (2005) Biological basis for the use of botanicals in osteoarthritis and rheumatoid arthritis: a review. Evid Based Complement Alternat Med 2:301-308.
88. Ahmed S, Wang N, Lalonde M et al (2004) Green tea polyphenol epigallocatechin-3-gallate (EGCG) differentially inhibits interleukin-1ß-induced expression of matrix metalloproteinase- 1 and -13 in human chondrocytes. J Pharmacol Exp Ther 308:767-773.
89. Boileau C, Pelletier J-P, Tardif F et al (2005) The regulation of human MMP-13 by licofelone, an inhibitor of cyclooxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 MAP kinase signalling pathway. Ann Rheum Dis 64:891-898.
90. Fosang AJ, Neame PJ, Last K et al (1992) The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases and cathepsin B. J Biol Chem 267:19470-19474.
91. Fosang AJ, Last K, Fujii Y et al (1998) Membrane-type MMP- (MMP-14) cleaves at three sites in the aggrecan interglobular domain. FEBS Lett 430:186-190.
92. Little CB, Flannery CR, Hughes CE et al (1999) Aggrecanase versus matrix metalloproteinases are involved in the catabolism of the interglobular domain of aggrecan in vitro. Biochem J 344:61-68.
93. Gilmore TD, Herscovitch M (2006) Inhibitors of NF- κB signaling: 785 and counting. Oncogene 25:6887-6899.
94. Sato H, Seiki M (1993) Regulatory mechanism of 92 kDa Type V collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 8:395-405